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ABSTRACT
Objectives: It is unclear whether insulin-like growth factor (IGF) function is involved in the 
pathophysiology of chronic fatigue syndrome (CFS). Unpublished data and reports in patient 
organization newsletters suggest that Acclydine, a food supplement, could be effective in the 
treatment of CFS by increasing biologically active IGF1 levels. Here we aimed to measure the 
IGF1 and IGF binding protein (IGFBP) 3 status of CFS patients compared to age- and gender- 
matched neighborhood controls, and to assess the effect of Acclydine on fatigue severity, 
functional impairment, and biologically active IGF1 level (IGFBP3/IGF1 ratio).
Design: A randomized, placebo-controlled, double-blind clinical trial.
Setting: Radboud University Nijmegen Medical Centre, The Netherlands.
Participants: Fifty-seven adult patients who fulfilled the US Centers for Disease Control and 
Prevention criteria for CFS. IGF status of 22 CFS patients was compared to that of 22 healthy 
age- and gender-matched neighborhood control individuals.
Intervention: Acclydine or placebo for 14 wk.
Outcome measures: Outcomes were fatigue severity (Checklist Individual Strength, subscale 
fatigue severity [CIS-fatigue]), functional impairment (Sickness Impact Profile-8 [SIP-8]), and 
biologically active IGF1 serum concentrations. Analyses were on an intention-to-treat basis.
Results: There was no difference in IGF status in 22 CFS patients compared to healthy age- 
and gender-matched control individuals. Treatment with Acclydine did not result in significant 
differences compared with the placebo group on any of the outcome measures: CIS-fatigue 
+1.1 (95% CI -4.4 to +6.5, p = 0.70), SIP-8 +59.1 (95% CI -201.7 to +319.8, p = 0.65), and IGFBP3/ 
IGF1 ratio -0.5 (95% CI -2.8 to +1.7, p = 0.63).
Conclusion: We found no differences in IGF1 status in CFS patients compared to healthy 
matched neighborhood controls. In addition, the results of this clinical trial do not demonstrate 
any benefit of Acclydine over placebo in the treatment of CFS.
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Editorial Commentary
Background: Chronic fatigue syndrome is a complicated and poorly 
understood illness. People with the condition experience tiredness that 
carries on for a long period of time and does not get better with rest. 
Other symptoms include sleeping problems, muscle and joint pains, 
concentration difficulties, and headaches. The causes of chronic fatigue 
syndrome are not known. There is evidence for the effectiveness of 
certain behavioral interventions, such as exercise therapy and cognitive 
behavioral therapy, in improving certain symptoms. However, some 
doctors are concerned that a food supplement called Acclydine, derived 
from a plant called Solanum dulcamara, is being used and promoted as a 
treatment for chronic fatigue syndrome when there is little evidence 
about the efficacy or safety of this supplement.
The researchers here carried out a randomized trial in The Netherlands, 
recruiting adult patients who met the internationally accepted criteria for 
chronic fatigue syndrome. The participants were allocated by chance to 
receive either 14 weeks of treatment with Acclydine together with amino 
acid supplements or, alternatively, placebo versions of the Acclydine and 
amino acid tablets. The researchers then measured participants' 
responses with respect to two primary outcome measures. One of these 
was how tired participants felt, which was measured using a subscale on 
a questionnaire called the Checklist Individual Strength scale (CIS- 
fatigue). The other primary outcome measure was “ functional impair­
ment,’’ which examines how well someone carries out their daily life, 
using the Sickness Impact Profile (SIP-8) scale. The secondary outcome 
measures included physical activity levels, day-to-day fatigue levels, and 
the levels of insulin-like growth factor 1 (IGF1) in blood, a hormone that's 
thought by some researchers to be related to the severity of chronic 
fatigue.
What the trial shows: In the trial, 57 people were randomized to receive 
either Acclydine plus amino acid supplements, or placebo tablets. When 
comparing scores on the primary outcome measures at the end of the 
trial, the researchers did not see significant differences between the 
treatment and placebo groups. Similarly, the results for secondary 
outcome measures in this trial did not show any significant differences 
between the treatment and placebo groups.
Strengths and limitations: Strengths of this study include the fact that 
it is one of the few properly designed studies of a product for which 
claims have been made of effectiveness in chronic fatigue syndrome. The 
study was designed as a double-blind trial, in which participants and 
investigators (those collecting the outcome data) did not know whether 
an individual received Acclydine or placebo. This procedure should help 
to minimize bias in assessing outcomes. A key limitation of this study is 
the relatively small number of participants. However, the investigators 
considered it unlikely that a larger trial would detect a clinically 
meaningful effect of Acclydine on these outcome measures for patients 
with chronic fatigue syndrome.
Contribution to the evidence: Systematic reviews of interventions for 
the treatment of chronic fatigue syndrome have found evidence for the 
efficacy of exercise therapy and cognitive behavioral therapy. This trial 
shows no evidence of efficacy of Acclydine plus amino acid supplements 
for the treatment of chronic fatigue.
The Editorial Commentary is written by PLoS staff, based on the reports of the 
academic editors and peer reviewers.
INTRODUCTION
C hronic fatigue syndrom e (CFS) is a m edically u nexp la ined  
syndrom e, charac te rized  by severe d isabling  fatigue fo r a 
p e rio d  o f  a t leas t 6 m o th a t has led  to  co n sid e rab le  
im p a irm en t in  daily fun c tio n in g  [1]. V arious accom panying  
sym ptom s may be p resen t, such as headache, jo in t an d  m uscle
pain , sore th ro a t, an d  im p aired  m em ory and  co n cen tra tion . 
O f  th e  m any th e ra p e u tic  in te rv en tio n s  th a t  have been  
un d ertak en , so fa r only cognitive behavioral therapy  and  
g rad ed  exercise therapy  have m et w ith success [2].
N eu roendocrino log ica l investigations have tr ie d  to eluci­
date  th e  pathophysiology o f CFS [3]. As CFS patien ts and  
ad u lt p a tien ts  w ith  a g row th  h o rm o n e  (GH) deficiency re p o r t 
sim ilar sym ptom s such as fatigue, myalgia, a d im in ished  
sense o f w ell-being, and  red u ced  physical capacity  [4,5] and  
tre a tm e n t o f G H -deficient adults w ith GH has m easurable 
effects on  physical fu n c tio n  an d  p e rcep tio n  o f fatigue [6], 
GH status is a focus o f this research.. C hanges in  th e  GH/ 
insulin-like g row th fac to r (IGF) 1 axis have b een  re p o r te d  in 
CFS and  fa tigue-re la ted  d isorders such as fibrom yalgia [7]. 
IGF1 studies in  CFS p a tien ts  have y ielded conflic ting  results: 
low [8,9], no rm al [10,11], an d  increased  [12] basal IGF1 levels 
have b e e n  fo u n d . S am p le  size, se le c tio n  o f  c o n tro ls , 
app ro p ria ten ess  o f m atching, and  selection  o f CFS patien ts 
w ith psychiatric co -m orb id ity  could  explain  the conflicting  
results.
D esp ite  th e  conflic ting  publica tions co ncern ing  IGF1 status 
in CFS patien ts , in  re cen t years th e re  have b een  rep o rts  in 
p a tie n t o rgan iza tion  new sletters th a t a new food  supp lem en t 
called A cclydine could  be an effective tre a tm e n t fo r CFS. The 
active in g red ien t o f A cclydine is an alkalo id  from  Solanum 
dulcamara. I t has b een  claim ed th a t A cclydine is effective 
because it  increases IGF1 co n cen tra tions in  CFS patien ts by 
stim ula ting  GH releasing  h o rm o n e  and, consequently , GH 
secretion . GH is converted  to  IGF1 in  the liver. IGF1 activates 
tyrosine kinase an d  in teg rin  recep to rs  and  stim ulates in tra ­
cellu lar lip id  and  glycogen synthesis.
Levels o f IGF b in d in g  p ro te in s  (IGFBPs), particu la rly  
IGFBP3, m odu la te  th e  biological activity o f IGF1, an d  the 
ra tio  o f IGFBP3 to IGF1 reflects IGF1 biological activity [13]. 
T h ere  are  u npub lished  observations suggesting th a t Accly- 
d ine  could  increase  th e  IGF1 plasm a co n cen tra tio n s  in 
healthy  hum ans an d  in  CFS patien ts . A n 8-wk con tro lled  
tr ia l w ith  A cclyd ine  in  c o m b in a tio n  w ith  am in o  ac id  
sup p lem en ta tio n  in  90 CFS patien ts has been  re p o r te d  to  
have a positive effect [14].
H owever, th e re  are, to o u r know ledge, no pub lished  peer- 
rev iew ed  s tud ies  in v es tig a tin g  th e  e ffec t o f  A cclydine. 
D oub le-b lind  random ized  co n tro lled  trials are  needed, fo r 
several reasons. First, this food  sup p lem en t is available on  the 
In te rn e t w ithou t p re sc rip tio n  an d  is thus easily accessible. 
Second, a lthough  th e  effects o f Acclydine tre a tm e n t have n o t 
b een  evaluated  thoroughly , th e re  a re  ongoing  studies in o th e r 
vu lnerab le  p a tie n t categories, such as in  cancer pa tien ts w ith 
ch ron ic  fatigue a fte r  tre a tm en t, b u t these studies are  n o t 
listed  in  the in te rn a tio n a l co n tro lled  tr ia l registry  C u rren t 
C on tro lled  Trials (h ttp://w w w .controlled-trials.com ).
F o r th e  reasons given above, we assessed th e  IGFBP3/IGF1 
status in  pa tien ts fulfilling the US C enters fo r Disease C on tro l 
an d  P reven tion  (CDC) c rite r ia  fo r CFS [1] and  in  healthy  
gender- an d  age-m atched  neig h b o rh o o d  contro ls, to  evaluate 
w hether th e re  are  in trin sic  d ifferences in  IGFBP3/IGF1 status 
betw een  the two groups. F u rth e rm o re , we investigated  the 
effect o f A cclydine on  IGF1 co n cen tra tio n , IGFBP3/IGF1 
ra tio , an d  C FS-related  sym ptom s in  a w ell-defined CFS 
p o p u la tio n  using  validated  ou tcom e m easures an d  a ra n d o m ­
ized doub le-b lind  p lacebo -con tro lled  design.
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METHODS
T he study was ap p ro v ed  by the m edical eth ical com m ittee  o f 
the R adboud  U niversity  N ijm egen M edical C entre. W ritten  
in fo rm ed  consen t was ob ta in ed  from  all pa rtic ip an ts  p r io r  to 
enro llm ent.
Participants
Patien ts w ere rec ru ited  th ro u g h  the  o u tp a tie n t clinic o f the 
D ep artm en t o f G eneral In te rn a l M edicine o f the  R adboud  
U niversity  N ijm egen M edical C en tre  an d  th ro u g h  an  adver­
tise m e n t in  th e  n ew sle tte r  o f  th e  D u tch  CFS p a tie n t 
o rg an iza tion  M E -S tichting  (h ttp://w w w .m e-cvs-stichting.nl). 
P atien ts w ere eligible fo r p a rtic ip a tio n  if they fulfilled the 
follow ing inclusion  criteria: they had  to  be betw een 18 and  65 
y o f age, an d  they h ad  to  fulfill th e  CDC consensus c rite r ia  fo r 
CFS [1]. A S tru c tu red  C linical In terv iew  fo r DSM-IV (SCID-1) 
was p e rfo rm ed  to  exclude p a tien ts  w ith c u rre n t psychiatric 
co -m o rb id ity  a n d  to  en su re  a h o m o g en eo u s g ro u p  o f 
patients.
P reg n an t o r  lac ta ting  w om en w ere excluded, as were 
patien ts w ith lactose in to le rance  and  p a tien ts  tak ing  psycho­
tro p ic  drugs o r  ex perim en ta l m edications.
A n ad d itiona l c rite r io n  to  be m et was an  IGFBP3/IGF1 
ra tio  g re a te r  th a n  2.5. W e asked  p a tie n ts  w ho co u ld  
po ten tia lly  p a rtic ip a te  in  the trial, if possible, to  b rin g  a 
healthy  n e ig h b o rh o o d  co n tro l ind iv idual o f sim ilar age, 
gender, body weight, an d  body height, to  com pare  IGF status. 
E xcept fo r contracep tives, the co n tro l individuals w ere n o t 
allowed to  take m edication .
Interventions
A cclydine an d  an iden tical placebo w ere delivered  by the 
m an u fac tu re r O p tip h a rm a . Each A cclydine capsule co n ­
ta in ed  250 m g o f th e  alkaloid. P atien ts took  a single daily 
dose on  an em pty  stom ach, w ith the follow ing decreasing  
A cclydine dosage schedule over a to ta l o f 14 wk: weeks 1-2, 
1,000 m g p e r  day; weeks 3-6 , 750 mg p e r  day; weeks 7-8 , 500 
mg p e r  day; weeks 9-10, 500 mg every 2 d; weeks 11-12, 250 
mg p e r  day; and  weeks 13-14, 250 m g every 2 d.
A cclyd ine t r e a tm e n t was co m b in ed  w ith  am ino  acid  
supplem ents to  p rov ide  sufficient essential and  nonessen tia l 
am ino acid  in take d u rin g  trea tm en t. P atien ts in  the  placebo 
g ro u p  received p lacebo A cclydine and  p lacebo am ino acid  
supplem ents.
T h ere  was no d ifference  in  taste, appearance , o r  packaging 
betw een the active supplem ents an d  the p lacebo capsules.
Design and Procedures
T he study was a p rospective , random ized , doub le-b lind , 
p lacebo -con tro lled  trial. T he effect o f A cclydine was assessed 
by p re- an d  post-tria l testing. P ost-tria l testing  was pe rfo rm ed  
a t the en d  o f th e  14-wk tre a tm e n t period . D uring  the post-tria l 
assessm ents, th e  patien ts w ere still tak ing  th e  tria l supp le­
m ents. All p artic ipan ts , investigators, and  labo ra to ry  te ch n i­
cians w ere b lin d ed  to th e  tre a tm e n t cond ition . IGF1 and  
IGFBP3 m easurem ents w ere also done in a b lin d ed  fashion.
Randomization
B efore the s ta rt o f the clinical tria l, th e  pharm acy  o f the 
hosp ita l p re p a re d  57 tre a tm e n t packages. R andom ization  and  
allocation  to  th e  tre a tm e n t o r  placebo g ro u p  was based on  a 
p a tie n t’s study num ber. A fte r accep tance  o f a p a tie n t by the
ju n io r  re sea rch e r (G. K. H. T.) and  th e  clinical psychologist 
(G. B.), th e  eligible p a tie n t received th e  low est study n u m b er 
available (1-57). T he pharm acy  held  th e  random iza tion  list 
th a t co rre la ted  th e  study n u m b er w ith the  tre a tm e n t group. 
To m ain ta in  balance over tim e, the concealed  random iza tion  
was done  in  blocks o f ten. T rea tm en ts  w ere g en era ted  
random ly  w ith in  th e  blocks using  a co m p u te r p ro g ram  (Excel, 
M icrosoft, h ttp://w w w .m icrosoft.com ).
Primary Outcome Measures
Fatigue severity. T he C hecklist Indiv idual S tren g th  is a 
reliab le  and  validated  se lf-repo rt questionnaire . W e used the 
C hecklist Indiv idual S treng th , subscale fatigue severity (CIS- 
fatigue) [15,16]. T he score on  this e igh t-item  scale ranges 
from  eigh t (no fatigue) to  56 (m axim ally fatigued). T he cu t-o ff 
p o in t was set a t 35 [17].
Functional impairment. T he Sickness Im pac t Profile-8 (SIP- 
8) m easures the influence o f sym ptom s on  daily function ing , 
u sing  the  follow ing e igh t subscales to ra te  b o th  physical and  
psychological disability: hom e m anagem ent, m obility, a le r t­
ness behavior, sleep/rest, am bula tion , social in te rac tions, 
work, an d  rec rea tio n  and  pastim es [18,19]. CFS p a tien ts  w ith 
substan tia l func tiona l im pairm en ts w ere included. Patien ts 
w ith scores above the cu t-o ff p o in t o f 800 w ere included.
Secondary Outcome Measures
Activity level. Besides se lf-repo rted  ou tcom e m easures, we 
m easured  physical activity w ith an ac tom eter. A n ac to m ete r is 
a small m otion-sensing  device a ttach ed  to  th e  ankle; it  was 
w orn  con tinuously  fo r 14 d d u rin g  th e  assessm ent periods. 
A fte r the 2-wk period , th e  average score over 12 d was 
co m p u ted  [20].
Daily fatigue level. D uring  th e  2-wk ac to m ete r period , 
p a tien ts  ra te d  th e ir  fa tigue level in  a com p la in t diary. They 
ra ted  th e ir  level o f fa tigue fo u r tim es a day on  a zero (no 
fatigue) to  fo u r (m axim ally fatigued) scale. T he fo u r scores fo r 
each day w ere sum m ed to p ro d u ce  the daily observed fatigue 
(DOF) score, w hich ranged  from  0 to  16 [21]. T he m ean  o f 12 
consecutive D OF scores was used.
Blood Samples
B lood sam ples o f th e  p a tien ts  an d  th e  m atched  n e ighbo rhood  
contro ls w ere taken  a t the  sam e tim e, and  th e  p a ired  b linded  
sam ples w ere han d led  in  an  iden tica l fashion. Serum  IGF1 
was m easured  by an im m une rad io m etric  assay (D iagnostic 
Systems L aborato ries , http://www.dslabs.com ). F o r IGF1, the 
in te r- an d  intra-assay coefficients o f varia tion  w ere 6.25% 
an d  4.93% , respectively. IGFBP3 was also assessed by an 
im m une rad io m etric  assay (Im m ulite, DPC, h ttp ://dpcw eb. 
com). F o r IGFBP3, the in te r- and  intra-assay coefficients o f 
varia tion  w ere 4.25% an d  1.3%, respectively.
Statistical Methods
F or all analyses SPSS 12.01 (SPSS, http://www.spss.com) was 
used.
Pow er calculations befo re  th e  s ta rt o f the  tria l show ed th a t 
22 persons w ere needed  in  each g ro u p  to  d e tec t a d ifference 
o f a t least one s tan d a rd  dev iation  (SD) on  th e  C IS-fatigue w ith 
a pow er o f 90% an d  a tw o-tailed  significance level o f 5%. 
A n tic ipa ting  a d ro p o u t ra te  o f 10%, a t least 49 persons 
needed  to  be recru ited . Analyses w ere p e rfo rm ed  on  an 
in te n tio n -to -tre a t basis.
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Table 1. Hormonal Blood Levels
Hormone Patients (n — 22) Controls (n -  22) p-Value (95% CI)
Mean (SD) Range (nm/l) Mean (SD) Range (nm/l)
IGF1 (nm/l) 37.0 (19.7) 18.6-96.1 36.9 (14.1) 18.6-76.1 0.98 (-10.3 to 10.6)
IGFBP3 (nm/l) 117.6 (60.1) 51.1-224.7 114.5 ( 54.7) 56.0-240.8 0.86 (-31.8 to 38.1)
Ratio IGFBP3/IGF1 3.7 (2.3) 0.89-9.24 3.5 (2.3) 1.37-9.84 0.82 (-1.2 to 1.5)
doi:10.1371/journal.pctr.0020019.t001
M issing values w ere rep laced  by way o f th e  last observation  
ca rried  forw ard. In d e p e n d e n t sam ple t-tests w ere pe rfo rm ed  
on  the change scores, defined  as th e  d ifference  betw een 
baseline scores and  th e  p o st-tre a tm en t scores a fte r  14 wk.
IG F d a ta  a re  g iven as m ean  ±  SD. T he  h o rm o n a l 
m easurem ents w ere analyzed by in d ep en d e n t sam ple t-test.
RESULTS
All pa tien ts w ere rec ru ited  betw een  February  2003 and  A pril 
2005.
In  to tal, 22 patien ts w ere able to  b rin g  a n e ighbo rhood  
con tro l individual (four m en an d  18 women). T he results o f 
the h o rm onal assessm ents are  show n in  T able 1. H orm onal 
values includ ing  th e  CFS p a tien ts  o f the o u tp a tie n t clinic and
p a tien ts  who d id  n o t m ee t th e  ho rm o n a l inclusion  c rite r ia  fo r 
p a rtic ip a tio n  in  th e  clinical tr ia l a re  rep o rted .
N o significant d ifferences w ere fo u n d  in  the  IGF status o f 
the  CFS patien ts versus the controls.
F igure 1 illustrates p a rtic ip a n t flow th ro u g h  the trial. In  
to tal, 112 patien ts w ere given in fo rm atio n  ab o u t the  study 
p ro toco l; 31 persons refused  to p artic ipa te , and  th e  m ain 
reason  given fo r refusal was th e  in tensity  o f th e  study. D ata 
ob ta in ed  from  26 o f th e  31 persons who chose n o t to  
p a rtic ip a te  show ed no significant d ifference in  age, n u m b er 
o f CDC sym ptom s, fa tigue severity, o r  func tiona l im p a irm en t 
betw een  the CFS p a tien ts  p a rtic ip a tin g  in  th e  clinical tria l 
an d  those who chose n o t to  p a rtic ip a te  (data n o t shown). 
T w enty-four p a tien ts  d id  n o t m ee t th e  inclusion criteria . A 
to ta l o f 57 patien ts w ere random ized  in  the clinical trial: 15 
p a tien ts  w ere rec ru ited  from  the o u tp a tie n t clinic, an d  42
Figure 1. CONSORT Flowchart 
doi:10.1371/journal.pctr.0020019.g001
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Table 2. Patient Characteristics
Acclydine Treatment in CFS
Characteristic Acclydine Group Placebo Group
(n -  30) (n -  27)
: Age, years 40.9 (9.4) 43.4 (11.2)
: Female 77% 59%
: CIS-fatigue 46.5 (7.4) 46.2 (7.9)
: SIP-8 1,484 (520.4) 1,317 (481.7)
: CDC symptoms 7.6 (1.4) 7.5 (1.3)
: Values are mean (SD), except for gender, which is given as percent female.
.  doi:10.1371/journal.pctr.0020019.t002
patien ts cam e in  response to th e  advertisem en t in  th e  p a tien t 
o rgan ization  new sletter. O ne p a tien t in  each arm  d ro p p e d  ou t 
a fter random ization , an d  as a consequence, in each arm , 
baseline da ta  fo r one p a tien t was ca rried  forw ard, an d  a 
sensitivity analysis was n o t requ ired . T he Acclydine and  placebo 
trea tm en ts  w ere well to lerated . N o im p o rta n t side effects w ere 
re p o r te d  in  e ith e r group. T he A cclydine and  placebo groups 
d id  n o t d iffer w ith respec t to age, gender, fatigue severity, 
im pairm en t, o r  n u m b er o f CDC sym ptom s (Table 2).
Primary Outcomes
No significant d ifferences in  change scores w ere found  
betw een the  tre a tm e n t and  p lacebo groups on  th e  p rim ary  
ou tcom e m easures (Table 3). T he CFS patien ts tre a te d  w ith 
A cclydine d id  n o t show a significant decrease in fatigue 
severity (CIS-fatigue +1.1 [95% CI -4 .4  to +6.5, p  — 0.70]) o r 
functional im p a irm en t (SIP-8 +59.1 [95% CI -20 1 .7  to  +319.8, 
p — 0.65]) com pared  to  the p lacebo group.
Secondary Outcomes
A ctom eter activity scores d id  n o t show significant d ifferences 
betw een the two groups. Analysis o f fatigue severity ra ted  
w ith the D OF d id  n o t show significant d ifferences either.
No significant d ifferences w ere fo u n d  betw een  th e  tr e a t­
m en t an d  placebo groups in  IGF1 b lood  level, IBFBP3 b lood
Table 3. Treatment Effect
Outcomes Evaluation Groupa Baselineb At 14 w kb Treatment Effect (95% CI) p-Value
Primary CIS-fatigue Acclydine 46.5 (7.4) 42.4 (11.6) 1.1 (-4.4 to 6.5) 0.70
Placebo 46.2 (7.9) 43.0 (12.6)
SIP-8 Acclydine 1,484.0 (520.4) 1,228.1 (619.7) 59.1 (-201.7 to 319.8) 0.65
Placebo 1,317.0 (481.7) 1,120.2 (543.0)
Secondary Actometer Acclydine 60.8 (20.5) 64.9 (23.4) 4.1 (-5.9 to 14.0) 0.42
Placebo 64.8 (25.2) 64.9 (23.5)
DOF Acclydine 8.6 (2.3) 8.0 (2.8) -0.2 (-1.2 to 0.9) 0.76
Placebo 7.7 (2.2) 7.0 (2.6)
IGF1 Acclydine 43.2 (32.1) 37.7 (22.0) -4.6 (-17.7 to 8.6) 0.49
Placebo 37.3 (18.0) 36.3 (18.8)
IGFBP3 Acclydine 163.4 (34.1) 160.6 (32.9) -1.7 (-17.5 to 14.0) 0.83
Placebo 168.9 (39.6) 164.3 (29.5)
IGFBP3/IGF1 ratio Acclydine 5.3 (3.7) 5.7 (3.2) -0.5 (-2.8 to 1.7)) 0.63
Placebo 5.6 (3.1) 5.4 (2.1)
aAcclydine group, n — 30; placebo group, n — 27. 
bValues are mean (SD).
A decline in CIS-fatigue, SIP-8, DOF scores, IGFBP3 scores or the IGFBP3/IGF1 ratio is considered a positive outcome, i.e., an improvement. A decline in actometer, IGF1, is considered a 
negative outcome. The treatment effect is considered positive when the improvement in the Acclydine group is larger than that of the placebo group. 
doi:10.1371/journal.pctr.0020019.t003
level, o r  IGFBP3/IGF1 ra tio  a t baseline; a fte r 4, 8, o r  14 wk of 
trea tm en t; o r  d u rin g  follow -up (Figure 2).
DISCUSSION
Interpretation
In  this ran d o m ized  co n tro lled  b lin d ed  clin ical tr ia l, no 
th e rap eu tic  effect o fA cclyd ine in  CFS was found . In  this study 
we also addressed  the issue o f a deficiency o f b ioactive IGF1. To 
co n tro l fo r un w an ted  stress effects an d  o th e r  confounders, the 
b lood  sam ples w ere taken  sim ultaneously  from  the patien ts 
an d  th e ir  m atched  neig h b o rh o o d  contro ls. F or each p a ir  o f 
p a tie n t and  con tro l, th e  m easurem ents o f IGF1 and  IGFBP3 
w ere p e rfo rm ed  in  th e  sam e run . In  add ition , we de tec ted  no 
d ifferences in  IGF1 orIG FB P3 co ncen tra tions in  CFS patien ts 
w ith o u t p sych ia tric  co -m o rb id ity  versus closely m atch ed  
healthy  neig h b o rh o o d  contro ls.
A lthough  the  sam ple size is relatively small, th e  results do 
n o t p o in t to  a d iffe ren t IGFBP3/IGF1 status in  CFS patien ts 
com pared  to  contro ls. These results do n o t su p p o rt the 
hypothesis th a t changes in  IGF1 and  IGFBP3 m etabolism  are 
involved in  th e  pathophysiology o f CFS.
Generalizability
In  this study we en ro lled  a rep resen ta tive  sam ple o f adu lt 
re fe rred  an d  n o n -re fe rred  CFS patien ts who fulfilled the 
in te rn a tio n a l CDC consensus c rite r ia  fo r CFS [1]. In  co n trast 
to previous in te rv en tio n  studies w ith cognitive behavioral 
the rapy  [22] o r  w ith a p o ly n u trien t supp lem en t [23] con ­
du c ted  by o u r  research  group , we excluded  p a tien ts  w ith 
psychiatric co -m orb id ity  to  exclude ho rm o n a l influences 
caused by c u rre n t psychiatric  co-m orbidity . T he m ean  fatigue 
severity an d  func tiona l im p a irm en t scores in  this study 
rep re sen t h igh  fatigue severity levels an d  h igh  functional 
im p a irm en t in  th e  CFS patien ts. C om pared  to  the previously 
m en tio n ed  in te rv en tio n  studies, the p a tien ts  in this clinical 
tria l re p o r te d  slightly low er fatigue and  func tiona l im p a ir­
m en t scores. Selection  o f CFS p a tien ts  w ith o u t c u rre n t 
psychiatric co -m orb id ity  could  explain  this difference.
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baseline
C Ratio IGF-BP3 / IGF-1, mean (sd)
Figure 2. Hormone Data of the Two Treatment Groups
(A) IGF1 concentration.
(B) IGFBP3 concentration.
(C) IGFBP3/IGF1 ratio. 
doi:10.1371/journal.pctr.0020019.g002
Overall Evidence
To o u r know ledge, this is the first pub lished  re p o r t o f a 
random ized  co n tro lled  tria l evaluating  the effect o f the food 
su p p lem en t A cclydine in  CFS p a tien ts . T he e ffec t was 
assessed by pre- an d  p ost-tr ia l testing  w ith validated  in s tru ­
m ents designed to  assess d iffe ren t d im ensions o f CFS as well 
as tre a tm e n t effects. T rea tm en t w ith A cclydine was n o t m ore 
effective th an  p lacebo  in  changing  se lf-repo rted  ou tcom e 
m easures, h o rm o n al b lood  levels, o r  physical activity.
The lack o f significant differences on  any o f  the d im ensions 
o f fatigue o r  the h o rm o n al assessm ents streng thens o u r 
overall findings.
P revious u n pub lished  studies by o thers o n  file a t the 
m an u fac tu re r claim ed th a t tre a tm e n t w ith A cclydine w ould 
be m ore effective in  CFS p a tien ts  w ith a h igher IGFBP3/IGF1 
ratio . Based on  this claim, we d id  a subset analysis fo r pa tien ts 
w ith a ra tio  g rea te r th an  4.5:19 CFS p a tien ts  in  the Acclydine 
g roup  and  20 in  the p lacebo  g roup  h ad  a ra tio  g rea te r th an  
4.5. N o significant d ifferences in  change scores w ere seen 
betw een  the subgroups in  any o f the ou tcom e m easures.
A second claim  was th a t A cclydine tre a tm e n t works by 
increasing  biologically active IGF1. H owever, assessm ent o f 
IGF1 co n cen tra tio n  and  IGFBP3/IGF1 values in  the Acclydine
g roup  a t baseline, 4 wk, and  8  wk d u rin g  trea tm en t, a t the end  
o f trea tm en t, and  a t follow -up (1 m o a fte r the tre a tm e n t 
period ) d id  n o t show a significant change.
The pow er o f o u r  study was sufficient to  d e tec t changes in 
tim e in  b o th  groups. Thus, the negative findings fo und  in  this 
random ized  co n tro lled  tria l c an n o t be exp la ined  by a pow er 
p rob lem . C onsidering  the re p o r te d  tre a tm e n t effect on  the 
p rim ary  ou tcom e m easures, we believe it is very unlikely th a t 
a la rger tr ia l w ould d e tec t a clinically m eaningful effect.
It is o f in te re s t to no te  th a t we d e tec ted  a m in o r placebo 
effect in  this study. This is in  accordance  w ith observations 
from  ea rlie r random ized  co n tro lled  clinical trials in  CFS [23­
25]. H owever, the m inim al decline in  fatigue severity and  
func tiona l im p a irm en t d u rin g  pre- and  p ost-tr ia l testing  in 
b o th  tre a tm en t g roups could  also be partly  exp la ined  by the 
p h en o m en o n  regression  to  the m ean  o r  a H aw thorne  effect.
We d id  n o t m o n ito r p a tie n t com pliance on  a daily basis. 
D u ring  the trial, p a tien ts  h ad  an  ap p o in tm en t by te lephone 
o r  a t the o u tp a tie n t clinic every 2 wk. D u ring  these a p p o in t­
m ents, we assessed w hether the capsules w ere taken  as 
d irec ted , and  the tre a tm e n t p ro to co l fo r the nex t 2 wk was 
discussed w ith the p a tien t. A lthough adherence  could  n o t be
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verified fully, th e re  is no  reason  to believe th a t lack o f 
adherence  can explain  the negative findings.
In  conclusion, this random ized  co n tro lled  tria l d id  n o t 
d em o n stra te  an  effect o f A cclydine on  biologically active 
IGF1, n o r  d id  it d em o n s tra te  any benefit in  C FS-related 
ou tcom e m easures. Thus, the findings o f this clinical tr ia l do 
n o t su p p o r t the use o f A cclydine in  th e  tre a tm e n t fo r CFS.
We feel th a t th e  negative results o f this tr ia l a re  im p o rta n t 
fo r two reasons: A cclydine is expensive, so p a tien ts  m ight be 
spend ing  a lo t o f m oney on  an ineffective tre a tm en t, and  it is 
also available w ithou t p re sc rip tio n  on  the In te rn e t, m aking it 
available to  p a tien ts  po ten tia lly  w ithou t a d o c to r’s oversight.
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